Back to News
Market Impact: 0.35
Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig
Source: marketbeat.com
Healthcare & BiotechM&A & RestructuringCorporate Guidance & Outlook
Lakefront Biotherapeutics plans to begin registrational studies in 2027 for gamgertamig, its lead T-cell engager. The development follows a broad restructuring of its legacy cell-therapy business and the acquisition of assets from Ouro Medicines, repositioning the company around its clinical-stage oncology pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
LKFT0.45
More News
- Paramount agrees invest $1.5 billion in domestic movies and create a board for editorial independence at CNN, CBS as part of deal for Warner Bros.
- Paramount and state AGs will settle lawsuit, allowing Warner Bros. merger to proceed, reports say
- Paramount Set to Settle Lawsuits, Clearing Way for Warner Bros. Deal
- Paramount settles with US states in step towards merger with Warner Bros
- Perpetual underdog AMD nips at Nvidia's heels as it joins the $1T club
- Paramount settles lawsuit blocking $110 billion Warner Bros. merger
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for Family Offices: A Stack by Decision Type
- Reading Conviction in the Tape: What Level 3 Order Book Data Really Tells Discretionary PMs